Literature DB >> 28512159

Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics.

Erik B Schelbert1, Hani N Sabbah2, Javed Butler2, Mihai Gheorghiade2.   

Abstract

Quantifying myocardial fibrosis (MF) with myocardial extracellular volume measures acquired during cardiovascular magnetic resonance promises to transform clinical care by advancing pathophysiologic understanding and fostering novel therapeutics. Extracellular volume quantifies MF by measuring the extracellular compartment depicted by the myocardial uptake of contrast relative to plasma. MF is a key domain of dysfunctional but viable myocardium among others (eg, microvascular dysfunction and cardiomyocyte/mitochondrial dysfunction). Although anatomically distinct, these domains may functionally interact. MF represents pathological remodeling in the heart associated with cardiac dysfunction and adverse outcomes likely mediated by interactions with the microvasculature and the cardiomyocyte. Reversal of MF improves key measures of cardiac dysfunction, so reversal of MF represents a likely mechanism for improved outcomes. Instead of characterizing the myocardium as homogenous tissue and using important yet still generic descriptors, such as thickness (hypertrophy) and function (diastolic or systolic), which lack mechanistic specificity, paradigms of cardiac disease have evolved to conceptualize myocardial disease and patient vulnerability based on the extent of disease involving its various compartments. Specifying myocardial compartmental involvement may then implicate cellular/molecular disease pathways for treatment and targeted pharmaceutical development and above all highlight the role of the cardiac-specific pathology in heart failure among myriad other changes in the heart and beyond. The cardiology community now requires phase 2 and 3 clinical trials to examine strategies for the regression/prevention of MF and eventually biomarkers to identify MF without reliance on cardiovascular magnetic resonance. It seems likely that efficacious antifibrotic therapy will improve outcomes, but definitive data are needed.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  T1 mapping; cardiovascular magnetic resonance; extracellular matrix; extracellular volume fraction; heart failure; myocardial fibrosis

Mesh:

Substances:

Year:  2017        PMID: 28512159     DOI: 10.1161/CIRCIMAGING.116.005619

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  14 in total

1.  The Prognostic Role of Tissue Characterisation using Cardiovascular Magnetic Resonance in Heart Failure.

Authors:  Robert D Adam; James Shambrook; Andrew S Flett
Journal:  Card Fail Rev       Date:  2017-11

2.  Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload.

Authors:  Arti V Shinde; Ya Su; Brad A Palanski; Kana Fujikura; Mario J Garcia; Nikolaos G Frangogiannis
Journal:  J Mol Cell Cardiol       Date:  2018-03-02       Impact factor: 5.000

3.  Left ventricular extracellular volume expansion does not predict recurrence of atrial fibrillation following catheter ablation.

Authors:  Suvai Gunasekaran; Daniel C Lee; Bradley P Knight; Jeremy D Collins; Lexiaozi Fan; Amar Trivedi; Ann B Ragin; James C Carr; Rod S Passman; Daniel Kim
Journal:  Pacing Clin Electrophysiol       Date:  2020-01-09       Impact factor: 1.976

4.  Left Ventricular Extracellular Volume Expansion Is Not Associated with Atrial Fibrillation or Atrial Fibrillation-mediated Left Ventricular Systolic Dysfunction.

Authors:  Suvai Gunasekaran; Daniel C Lee; Bradley P Knight; Lexiaozi Fan; Jeremy D Collins; Kelvin Chow; James C Carr; Rod Passman; Daniel Kim
Journal:  Radiol Cardiothorac Imaging       Date:  2020-04-23

5.  Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial.

Authors:  Gavin A Lewis; Erik B Schelbert; Josephine H Naish; Emma Bedson; Susanna Dodd; Helen Eccleson; Dannii Clayton; Beatriz Duran Jimenez; Theresa McDonagh; Simon G Williams; Anne Cooper; Colin Cunnington; Fozia Zahir Ahmed; Rajavarma Viswesvaraiah; Stuart Russell; Stefan Neubauer; Paula R Williamson; Christopher A Miller
Journal:  Cardiovasc Drugs Ther       Date:  2019-08       Impact factor: 3.727

6.  Association of fitness and body fatness with left ventricular mass: The Heart Health Study.

Authors:  Renee J Rogers; Erik B Schelbert; Wei Lang; Yaron Fridman; Nalingna Yuan; John M Jakicic
Journal:  Obes Sci Pract       Date:  2019-12-04

7.  Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction.

Authors:  Adam K McDiarmid; Peter P Swoboda; Bara Erhayiem; Katrina A Bounford; Petra Bijsterveld; Keith Tyndall; Graham J Fent; Pankaj Garg; Laura E Dobson; Tarique A Musa; James R J Foley; Klaus K Witte; Mark T Kearney; John P Greenwood; Sven Plein
Journal:  J Am Heart Assoc       Date:  2019-12-19       Impact factor: 5.501

8.  Multinuclear MRI to disentangle intracellular sodium concentration and extracellular volume fraction in breast cancer.

Authors:  Carlotta Ianniello; Linda Moy; Justin Fogarty; Freya Schnabel; Sylvia Adams; Deborah Axelrod; Leon Axel; Ryan Brown; Guillaume Madelin
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

9.  Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis.

Authors:  Eric Y Yang; Mohamad G Ghosn; Mohammad A Khan; Nickalaus L Gramze; Gerd Brunner; Faisal Nabi; Vijay Nambi; Sherif F Nagueh; Duc T Nguyen; Edward A Graviss; Erik B Schelbert; Christie M Ballantyne; William A Zoghbi; Dipan J Shah
Journal:  Circ Cardiovasc Imaging       Date:  2019-12-16       Impact factor: 7.792

10.  Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome.

Authors:  Erik B Schelbert; Yaron Fridman; Timothy C Wong; Hussein Abu Daya; Kayla M Piehler; Ajay Kadakkal; Christopher A Miller; Martin Ugander; Maren Maanja; Peter Kellman; Dipan J Shah; Kaleab Z Abebe; Marc A Simon; Giovanni Quarta; Michele Senni; Javed Butler; Javier Diez; Margaret M Redfield; Mihai Gheorghiade
Journal:  JAMA Cardiol       Date:  2017-09-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.